Cell therapy using encapsulated cells producing endostatin

Area of Science:

• Biomedical Engineering
• Cancer Biology
• Drug Delivery Systems

Background:

• Glioblastoma treatment remains challenging despite aggressive therapies, with poor patient prognosis.
• Anti-angiogenic therapy, using agents like endostatin, could potentially delay glioblastoma recurrence.
• Challenges include endostatin's short half-life and the blood-brain barrier, limiting its systemic use.

Purpose of the Study:

• To develop and evaluate genetically engineered cells secreting endostatin, encapsulated for sustained local delivery.
• To assess the efficacy of this localized endostatin delivery in a rat glioma model.
• To investigate the impact on tumor vasculature, microcirculation, and cell invasion.

Main Methods:

• Genetically engineered human embryonal kidney 293 cells transfected with the endostatin gene.
• Encapsulation of these cells within calcium cross-linked alginate gel beads for sustained release.
• Implantation of alginate beads into rat brains and assessment of cell viability and endostatin release.
• Intravital video microscopy to visualize anti-angiogenic effects on C6 rat glioma.

Main Results:

• Alginate-encapsulated cells demonstrated sustained endostatin release for up to 12 months with moderate cell viability loss.
• Endostatin significantly affected tumor-associated microcirculation, reducing vessel density, diameter, and functionality.
• Normal microcirculation remained unaffected, indicating targeted anti-angiogenic activity.
• Tumor cell migration and invasion were substantially reduced in endostatin-treated animals.

Conclusions:

• Encapsulated, engineered cells offer a viable strategy for sustained local endostatin delivery.
• This localized therapy effectively targets and inhibits glioblastoma angiogenesis and progression.
• The approach shows potential for improving glioblastoma treatment by overcoming delivery challenges.